CN103492377B - 作为pim激酶抑制剂的三唑并吡啶化合物 - Google Patents
作为pim激酶抑制剂的三唑并吡啶化合物 Download PDFInfo
- Publication number
- CN103492377B CN103492377B CN201280020416.9A CN201280020416A CN103492377B CN 103492377 B CN103492377 B CN 103492377B CN 201280020416 A CN201280020416 A CN 201280020416A CN 103492377 B CN103492377 B CN 103492377B
- Authority
- CN
- China
- Prior art keywords
- triazolo
- pyridin
- pyrrolidin
- ethyl
- trifluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *c1cc2ccc(C=O)nc2c(*)c1* Chemical compound *c1cc2ccc(C=O)nc2c(*)c1* 0.000 description 17
- RGZOKEBXMBZDQX-UHFFFAOYSA-N CC(C)NC(c(cc1)cc2c1ccc(-c1nnc3[n]1cc(C(C)N(CC1)CC1N)cc3)n2)=O Chemical compound CC(C)NC(c(cc1)cc2c1ccc(-c1nnc3[n]1cc(C(C)N(CC1)CC1N)cc3)n2)=O RGZOKEBXMBZDQX-UHFFFAOYSA-N 0.000 description 1
- BDNLPODBNQPLKV-YKSBVNFPSA-N CC(C)NC(c(cc1)cc2c1ccc(C1=CCCN=C3N1C=C([C@@H](C)N(CC1)C[C@H]1N=C)C=C3)n2)=O Chemical compound CC(C)NC(c(cc1)cc2c1ccc(C1=CCCN=C3N1C=C([C@@H](C)N(CC1)C[C@H]1N=C)C=C3)n2)=O BDNLPODBNQPLKV-YKSBVNFPSA-N 0.000 description 1
- YLJYLGRGQSKUGD-FDDCHVKYSA-N CC(C)Oc1c(C)c(nc(cc2)-c3nnc4[n]3cc([C@H](C(F)(F)F)N(CC3)C[C@H]3N)cc4)c2cc1 Chemical compound CC(C)Oc1c(C)c(nc(cc2)-c3nnc4[n]3cc([C@H](C(F)(F)F)N(CC3)C[C@H]3N)cc4)c2cc1 YLJYLGRGQSKUGD-FDDCHVKYSA-N 0.000 description 1
- XUEKYWJTUWKUMQ-NFJWQWPMSA-N CC(CC1)(CN1[C@@H](C(F)(F)F)c1ccc(NN)nc1)O Chemical compound CC(CC1)(CN1[C@@H](C(F)(F)F)c1ccc(NN)nc1)O XUEKYWJTUWKUMQ-NFJWQWPMSA-N 0.000 description 1
- GOTHDSMMSRFDRN-UHFFFAOYSA-N CC(c1c[n]2c(-c3ccc(cccc4C(C)(C)C)c4n3)nnc2cc1)N(CC1)CC1N Chemical compound CC(c1c[n]2c(-c3ccc(cccc4C(C)(C)C)c4n3)nnc2cc1)N(CC1)CC1N GOTHDSMMSRFDRN-UHFFFAOYSA-N 0.000 description 1
- UITKDHDWVARLQO-UHFFFAOYSA-N CC(c1c[n]2c(-c3nc(c(OCC4CC4)ccc4)c4cc3)nnc2cc1)N1CCCC1 Chemical compound CC(c1c[n]2c(-c3nc(c(OCC4CC4)ccc4)c4cc3)nnc2cc1)N1CCCC1 UITKDHDWVARLQO-UHFFFAOYSA-N 0.000 description 1
- QAABCQXVTAXAEI-FDDCHVKYSA-N CC1(COc2cccc3ccc(-c4nnc5[n]4cc([C@H](C(F)(F)F)N(CC4)C[C@H]4N)cc5)nc23)COC1 Chemical compound CC1(COc2cccc3ccc(-c4nnc5[n]4cc([C@H](C(F)(F)F)N(CC4)C[C@H]4N)cc5)nc23)COC1 QAABCQXVTAXAEI-FDDCHVKYSA-N 0.000 description 1
- OCFXSJTVJGSQAW-NRFANRHFSA-N CCN[C@@H]1CN(CC2=C[I]3C(c4nc(cc(cc5)C(NC6(C)CC6)=O)c5cc4)=NN=C3C=C2)CC1 Chemical compound CCN[C@@H]1CN(CC2=C[I]3C(c4nc(cc(cc5)C(NC6(C)CC6)=O)c5cc4)=NN=C3C=C2)CC1 OCFXSJTVJGSQAW-NRFANRHFSA-N 0.000 description 1
- YLAUFSGXWBUQQZ-PSGUAHCZSA-N CCOCCOc(cc1)cc2c1ccc(-c1nnc3[n]1cc([C@@H](CC(CC1)CCC1N)C(F)(F)F)cc3)n2 Chemical compound CCOCCOc(cc1)cc2c1ccc(-c1nnc3[n]1cc([C@@H](CC(CC1)CCC1N)C(F)(F)F)cc3)n2 YLAUFSGXWBUQQZ-PSGUAHCZSA-N 0.000 description 1
- BXCWHNANJBUOFR-CAWMZFRYSA-N CCSc1cccc(cc2)c1nc2-c1nnc2[n]1cc([C@H](C(F)(F)F)N(CC1)CC1N)cc2 Chemical compound CCSc1cccc(cc2)c1nc2-c1nnc2[n]1cc([C@H](C(F)(F)F)N(CC1)CC1N)cc2 BXCWHNANJBUOFR-CAWMZFRYSA-N 0.000 description 1
- DEYSFSVAZNCSND-UHFFFAOYSA-N COc1cccc(cc2)c1nc2-c1nnc2[n]1cc(C(C(F)(F)F)N1CCCC1)cc2 Chemical compound COc1cccc(cc2)c1nc2-c1nnc2[n]1cc(C(C(F)(F)F)N1CCCC1)cc2 DEYSFSVAZNCSND-UHFFFAOYSA-N 0.000 description 1
- YYQSLOAQBYVWDV-JVSMRNJESA-O C[C@@H](COc1cc2nc(C(N(C=C([C@@H](CC(CC3)CCC3N)C(F)(F)F)C=C3)C3=N)=[NH2+])ccc2cc1)OC Chemical compound C[C@@H](COc1cc2nc(C(N(C=C([C@@H](CC(CC3)CCC3N)C(F)(F)F)C=C3)C3=N)=[NH2+])ccc2cc1)OC YYQSLOAQBYVWDV-JVSMRNJESA-O 0.000 description 1
- HSUPIAUXDPPNHH-FMKFIRIRSA-N C[C@@H](COc1cccc(cc2)c1nc2-c1nnc2[n]1cc([C@H](C(F)(F)F)N(CC1)C[C@H]1N)cc2)OC Chemical compound C[C@@H](COc1cccc(cc2)c1nc2-c1nnc2[n]1cc([C@H](C(F)(F)F)N(CC1)C[C@H]1N)cc2)OC HSUPIAUXDPPNHH-FMKFIRIRSA-N 0.000 description 1
- GOTHDSMMSRFDRN-APWZRJJASA-N C[C@H](c1c[n]2c(-c3ccc(cccc4C(C)(C)C)c4n3)nnc2cc1)N(CC1)C[C@H]1N Chemical compound C[C@H](c1c[n]2c(-c3ccc(cccc4C(C)(C)C)c4n3)nnc2cc1)N(CC1)C[C@H]1N GOTHDSMMSRFDRN-APWZRJJASA-N 0.000 description 1
- MCYANSUGMVLNJX-UQBPGWFLSA-N Cc1n[n](C)c(-c2c(C)c3nc(-c4nnc5[n]4cc([C@H](C(F)(F)F)N(CC4)C[C@H]4N)cc5)ccc3cc2)c1 Chemical compound Cc1n[n](C)c(-c2c(C)c3nc(-c4nnc5[n]4cc([C@H](C(F)(F)F)N(CC4)C[C@H]4N)cc5)ccc3cc2)c1 MCYANSUGMVLNJX-UQBPGWFLSA-N 0.000 description 1
- TXHJMIVRUHPNNJ-BPNWFJGMSA-N NC[C@@H](CC1)CN1C(C(F)(F)F)c1c[n]2c(-c3ccc(cccc4OCC5CC5)c4n3)nnc2cc1 Chemical compound NC[C@@H](CC1)CN1C(C(F)(F)F)c1c[n]2c(-c3ccc(cccc4OCC5CC5)c4n3)nnc2cc1 TXHJMIVRUHPNNJ-BPNWFJGMSA-N 0.000 description 1
- YXSUDUADIAHANM-KSFYIVLOSA-N N[C@@H](CC1)CN1[C@@H](C(F)(F)F)c1c[n]2c(-c(cc3)nc4c3ccc(F)c4C3CC3)nnc2cc1 Chemical compound N[C@@H](CC1)CN1[C@@H](C(F)(F)F)c1c[n]2c(-c(cc3)nc4c3ccc(F)c4C3CC3)nnc2cc1 YXSUDUADIAHANM-KSFYIVLOSA-N 0.000 description 1
- HMWLLQIXSYMATL-XPTWASSNSA-N N[C@@H](CC1)CN1[C@@H](C(F)(F)F)c1c[n]2c(-c3ccc(ccc(OC(CCC4)[C@@H]4O)c4)c4n3)nnc2cc1 Chemical compound N[C@@H](CC1)CN1[C@@H](C(F)(F)F)c1c[n]2c(-c3ccc(ccc(OC(CCC4)[C@@H]4O)c4)c4n3)nnc2cc1 HMWLLQIXSYMATL-XPTWASSNSA-N 0.000 description 1
- HSUHIVHHBJFRCO-IFXJQAMLSA-N N[C@@H](CC1)CN1[C@@H](C(F)(F)F)c1c[n]2c(-c3ccc(cccc4O)c4n3)nnc2cc1 Chemical compound N[C@@H](CC1)CN1[C@@H](C(F)(F)F)c1c[n]2c(-c3ccc(cccc4O)c4n3)nnc2cc1 HSUHIVHHBJFRCO-IFXJQAMLSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161446902P | 2011-02-25 | 2011-02-25 | |
| US61/446,902 | 2011-02-25 | ||
| PCT/US2012/026572 WO2012154274A1 (en) | 2011-02-25 | 2012-02-24 | Triazolopyridine compounds as pim kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103492377A CN103492377A (zh) | 2014-01-01 |
| CN103492377B true CN103492377B (zh) | 2016-04-20 |
Family
ID=46000320
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280020416.9A Expired - Fee Related CN103492377B (zh) | 2011-02-25 | 2012-02-24 | 作为pim激酶抑制剂的三唑并吡啶化合物 |
Country Status (32)
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2671748T3 (es) | 2011-07-21 | 2018-06-08 | Tolero Pharmaceuticals, Inc. | Inhibidores heterocíclicos de proteína quinasas |
| MX2014011419A (es) * | 2012-04-25 | 2014-11-25 | Hoffmann La Roche | Clorhidrato de (3,4-dicloro-fenil)-((s)-3-propil-pirrolidin-3-il)- metanona y procesos de manufacturacion. |
| ES2649156T3 (es) | 2013-01-14 | 2018-01-10 | Incyte Holdings Corporation | Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim |
| CA2897333C (en) | 2013-01-15 | 2021-07-06 | Incyte Corporation | Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors |
| CR20160135A (es) | 2013-08-23 | 2016-08-05 | Incyte Corp | Compuestos de carboxamida de furo y tienopiridina útiles como inhibidores de cinasas pim |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| WO2016010897A1 (en) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors |
| US9540347B2 (en) | 2015-05-29 | 2017-01-10 | Incyte Corporation | Pyridineamine compounds useful as Pim kinase inhibitors |
| TWI734699B (zh) | 2015-09-09 | 2021-08-01 | 美商英塞特公司 | Ｐｉｍ激酶抑制劑之鹽 |
| TW201718546A (zh) | 2015-10-02 | 2017-06-01 | 英塞特公司 | 適用作pim激酶抑制劑之雜環化合物 |
| WO2017205536A2 (en) * | 2016-05-24 | 2017-11-30 | Genentech, Inc. | Therapeutic compounds and uses thereof |
| WO2019113487A1 (en) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| WO2019200254A1 (en) | 2018-04-13 | 2019-10-17 | Tolero Pharmaceuticals, Inc. | Pim kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancer |
| WO2020017569A1 (ja) | 2018-07-17 | 2020-01-23 | 日本ケミファ株式会社 | Ｔ型カルシウムチャネル阻害剤 |
| CN108912032A (zh) * | 2018-08-13 | 2018-11-30 | 南通大学 | 一种（3s，4r）-4-甲基吡咯烷-3-基氨基甲醇叔丁酯盐酸盐的化学合成方法 |
| CN109053526A (zh) * | 2018-08-13 | 2018-12-21 | 南通大学 | 一种（3r，4s）-4-甲基吡咯烷-3-基氨基甲酸叔丁酯盐酸盐的化学合成方法 |
| WO2020157709A1 (en) | 2019-02-01 | 2020-08-06 | Pfizer Inc. | Combination of a cdk inhibitor and a pim inhibitor |
| CA3127502A1 (en) | 2019-02-12 | 2020-08-20 | Sumitomo Dainippon Pharma Oncology, Inc. | Formulations comprising heterocyclic protein kinase inhibitors |
| US20220056043A1 (en) * | 2019-02-19 | 2022-02-24 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Nitrogen-containing fused cyclic compound, preparation method therefor and use thereof |
| AU2020250468A1 (en) | 2019-03-29 | 2021-11-04 | Kinki University | Use of T-type calcium channel blocker for treating pruritus |
| CN111171023B (zh) * | 2020-01-10 | 2021-12-21 | 中国药科大学 | 一种具有Pim1抑制活性的化合物及其制备方法与医药用途 |
| CN120302975A (zh) | 2022-10-31 | 2025-07-11 | 住友制药美国公司 | 治疗骨髓增生性肿瘤的pim1抑制剂 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010022076A1 (en) * | 2008-08-19 | 2010-02-25 | Array Biopharma Inc. | Triazolopyridine compounds as pim kinase inhibitors |
| WO2010022081A1 (en) * | 2008-08-19 | 2010-02-25 | Array Biopharma Inc. | Triazolopyridine compounds as pim kinase inhibitors |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA02004735A (es) | 1999-11-12 | 2003-01-28 | Orive Javier Uhthoff | Compuestos heteroaromaticos, biciclicos y triciclicos. |
| UA75055C2 (uk) * | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
| CN1173975C (zh) | 2000-04-27 | 2004-11-03 | 山之内制药株式会社 | 咪唑并吡啶衍生物 |
| DE10038019A1 (de) | 2000-08-04 | 2002-02-14 | Bayer Ag | Substituierte Triazolopyrid(az)ine |
| OA12552A (en) | 2001-03-09 | 2006-06-06 | Pfizer Prod Inc | Triazolopyridines as anti-inflammatory agents. |
| US7227006B2 (en) | 2002-01-19 | 2007-06-05 | Sanofi-Aventis Deutschland Gmbh | PIM-3 kinase as a target for type 2 diabetes mellitus |
| KR101075812B1 (ko) | 2002-12-18 | 2011-10-25 | 버텍스 파마슈티칼스 인코포레이티드 | 단백질 키나제 억제제로서의 트리아졸로피리다진 |
| DE60326646D1 (de) | 2002-12-18 | 2009-04-23 | Vertex Pharma | Benzisoxazolderivate, die sich als inhibitoren von proteinkinasen eigen |
| US20050164300A1 (en) | 2003-09-15 | 2005-07-28 | Plexxikon, Inc. | Molecular scaffolds for kinase ligand development |
| US20050256309A1 (en) | 2004-05-12 | 2005-11-17 | Altenbach Robert J | Tri-and bi-cyclic heteroaryl histamine-3 receptor ligands |
| EP1781655A2 (en) | 2004-08-18 | 2007-05-09 | Pharmacia & Upjohn Company LLC | Triazolopyridine compounds useful for the treatment of inflammation |
| ES2330872T3 (es) | 2004-12-01 | 2009-12-16 | Merck Serono Sa | Derivados de (1,2,4)triazolo(4,3-a)piridina para el tratamiento de enfermedades hiperproliferativas. |
| JP5238506B2 (ja) | 2005-10-06 | 2013-07-17 | エグゼリクシス， インコーポレイテッド | Ｐｉｍ−１および／またはｐｉｍ−３のピリドピリミジノンインヒビター |
| WO2007087250A2 (en) | 2006-01-23 | 2007-08-02 | Amira Pharmaceuticals, Inc. | Tricyclic inhibitors of 5-lipoxygenase |
| TW200808802A (en) | 2006-06-06 | 2008-02-16 | Schering Corp | Imidazopyrazines as protein kinase inhibitors |
| CN101600718B (zh) | 2006-11-06 | 2013-07-03 | 特雷罗药物股份有限公司 | 咪唑并[1,2-b]哒嗪和吡唑并[1,5-a]嘧啶衍生物及其作为蛋白激酶抑制剂的用途 |
| WO2008082839A2 (en) | 2006-12-29 | 2008-07-10 | Abbott Laboratories | Pim kinase inhibitors as cancer chemotherapeutics |
| RU2009136263A (ru) * | 2007-03-02 | 2011-04-10 | Шеринг Корпорейшн (US) | Производные бензимидазола и способы их применения |
| EP2139888A2 (en) * | 2007-03-28 | 2010-01-06 | Array Biopharma, Inc. | Imidazoý1,2-a¨pyridine compounds as receptor tyrosine kinase inhibitors |
| WO2008124323A1 (en) * | 2007-04-03 | 2008-10-16 | Array Biopharma Inc. | Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors |
| AR071717A1 (es) | 2008-05-13 | 2010-07-07 | Array Biopharma Inc | Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer. |
| US20110184013A1 (en) * | 2008-10-01 | 2011-07-28 | Shelley Allen | Imidazo[1,2-a]Pyridine Compounds As Receptor Tyrosine Kinase Inhibitors |
| JP2012521428A (ja) * | 2009-03-23 | 2012-09-13 | メルク・シャープ・エンド・ドーム・コーポレイション | 疼痛治療用のｐ２ｘ３受容体アンタゴニスト |
-
2012
- 2012-02-24 HR HRP20160134TT patent/HRP20160134T1/hr unknown
- 2012-02-24 RU RU2013143292/04A patent/RU2598846C2/ru not_active IP Right Cessation
- 2012-02-24 AR ARP120100626A patent/AR085489A1/es active IP Right Grant
- 2012-02-24 UA UAA201311350A patent/UA111075C2/uk unknown
- 2012-02-24 WO PCT/US2012/026572 patent/WO2012154274A1/en not_active Ceased
- 2012-02-24 RS RS20160095A patent/RS54586B1/sr unknown
- 2012-02-24 CN CN201280020416.9A patent/CN103492377B/zh not_active Expired - Fee Related
- 2012-02-24 MX MX2013009820A patent/MX339899B/es active IP Right Grant
- 2012-02-24 PL PL12716770T patent/PL2678329T3/pl unknown
- 2012-02-24 DK DK12716770.8T patent/DK2678329T3/da active
- 2012-02-24 SG SG2013064324A patent/SG192944A1/en unknown
- 2012-02-24 UY UY0001033924A patent/UY33924A/es not_active Application Discontinuation
- 2012-02-24 SI SI201230453A patent/SI2678329T1/sl unknown
- 2012-02-24 PH PH1/2013/501754A patent/PH12013501754A1/en unknown
- 2012-02-24 ES ES12716770.8T patent/ES2563152T3/es active Active
- 2012-02-24 US US14/001,657 patent/US8889704B2/en not_active Expired - Fee Related
- 2012-02-24 EP EP12716770.8A patent/EP2678329B1/en active Active
- 2012-02-24 CA CA2828269A patent/CA2828269C/en not_active Expired - Fee Related
- 2012-02-24 ME MEP-2016-35A patent/ME02365B/me unknown
- 2012-02-24 AU AU2012254082A patent/AU2012254082B2/en not_active Ceased
- 2012-02-24 BR BR112013021675A patent/BR112013021675A2/pt not_active Application Discontinuation
- 2012-02-24 JP JP2013555610A patent/JP6039585B2/ja not_active Expired - Fee Related
- 2012-02-24 KR KR1020137025297A patent/KR101940338B1/ko not_active Expired - Fee Related
- 2012-02-24 HU HUE12716770A patent/HUE027675T2/en unknown
- 2012-02-29 TW TW101106629A patent/TWI529170B/zh not_active IP Right Cessation
-
2013
- 2013-08-23 CL CL2013002446A patent/CL2013002446A1/es unknown
- 2013-08-25 IL IL228108A patent/IL228108A/en active IP Right Grant
- 2013-09-11 CR CR20130460A patent/CR20130460A/es unknown
- 2013-09-17 ZA ZA2013/06997A patent/ZA201306997B/en unknown
- 2013-09-18 CO CO13222097A patent/CO6771441A2/es unknown
-
2016
- 2016-02-16 CY CY20161100127T patent/CY1117197T1/el unknown
- 2016-02-22 SM SM201600052T patent/SMT201600052B/xx unknown
- 2016-02-24 JP JP2016032675A patent/JP2016106118A/ja not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010022076A1 (en) * | 2008-08-19 | 2010-02-25 | Array Biopharma Inc. | Triazolopyridine compounds as pim kinase inhibitors |
| WO2010022081A1 (en) * | 2008-08-19 | 2010-02-25 | Array Biopharma Inc. | Triazolopyridine compounds as pim kinase inhibitors |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103492377B (zh) | 作为pim激酶抑制剂的三唑并吡啶化合物 | |
| CN104520290B (zh) | 酰氨基螺环酰胺和磺酰胺衍生物 | |
| CN102985417B (zh) | 作为jak1抑制剂的哌啶-4-基氮杂环丁烷衍生物 | |
| EP2334677B1 (en) | Triazolopyridine compounds as pim kinase inhibitors | |
| CN102458581B (zh) | 作为JANUS激酶抑制剂的吡唑-4-基-吡咯并[2，3-d]嘧啶和吡咯-3-基-吡咯并[2，3-d]嘧啶的N-(杂)芳基-吡咯烷衍生物 | |
| CN105051029B (zh) | 可用作pim激酶抑制剂的噻唑甲酰胺和吡啶甲酰胺化合物 | |
| KR101930603B1 (ko) | 피롤로[2,3-d]피리미디닐, 피롤로[2,3-b]피라지닐 및 피롤로[2,3-d]피리디닐 아크릴아미드 | |
| TW202204355A (zh) | 稠合三環kras抑制劑 | |
| CN112135824A (zh) | 作为免疫调节剂的杂环化合物 | |
| RS64018B1 (sr) | Makrocikli kao modulatori transmembranskog regulatora provodnosti cistične fibroze, njihove farmaceutske kompozicije, njihova upotreba u lečenju cistične fibroze i proces njihove izrade | |
| WO2019174533A1 (zh) | Pd-1/pd-l1类小分子抑制剂及其在药物中的应用 | |
| CN105658653A (zh) | 可用作pim激酶抑制剂的呋喃并-和噻吩并-吡啶甲酰胺化合物 | |
| HK40086960A (zh) | 肽基精氨酸脱亚胺酶的大环抑制剂 | |
| HK1190714B (en) | Triazolopyridine compounds as pim kinase inhibitors | |
| NZ615300B2 (en) | Triazolopyridine compounds as pim kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160420 Termination date: 20210224 |